Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.
- None.
- None.
Insights
Analyzing...
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.
Fireside Chat Details:
Date: | Thursday, September 8, 2022 | |
Time: | 11:35 am -12:05 pm ET | |
Presenters: | Ian Mortimer, President and CEO Chris Von Seggern, CCO |
A webcast of the fireside chat will be available on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
